MONMOUTH JUNCTION, N.J., Nov. 17, 2016 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its European Union approved CytoSorb® cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients worldwide, reports highlights from the SepsEast 2016 Congress.

CytoSorbents Logo. (PRNewsFoto/CytoSorbents)

The SepsEast 2016 Congress, held from November 9-11, 2016 in Budapest, Hungary, is one of the most important critical care conferences in eastern and central Europe, drawing approximately 450 physicians and healthcare professionals from more than 25 countries.  CytoSorbents was the exclusive Diamond Sponsor at the conference.

The CytoSorbents sponsored research symposium was well-attended with more than 200 participants interested in learning more about CytoSorb from the following agenda:

  • CytoSorb – Cytokine removal in SIRS and Sepsis
    Chair: Dr. Dana Tomescu, Romania, and Dr. Janos Fazakas, Hungary
  • Adsorption of cytokines early in septic shock – The ACESS trial Interim Analysis
    Prof. Zsolt Molnar, Hungary
  • When to start the therapy? Early vs late treatment in septic shock
    Dr. Klaus Kogelmann, Germany
  • Panel discussion: Is the time ripe for a CytoSorb consensus?
    Z. Molnar A. Nierhaus, K. Kogelmann, D. Tomescu, J. Fazakas

In addition, two additional lectures featured CytoSorb in the main scientific program of the conference.

  • Immunological interventions in sepsis – past, present, future
    Dr. Axel Nierhaus, Germany
  • Cytokine adsorption – its place and perspectives
    Dr. Dana Tomescu, Romania

Highlights from the meeting:

  • Prof. Zsolt Molnar presented an interim analysis of the randomized, controlled ACESS Trial, evaluating the early use of CytoSorb in patients with septic shock.  The early data suggest strong improvements in hemodynamic stability in patients receiving both standard of care therapy and CytoSorb, versus those receiving standard of care alone.
  • Dr. Klaus Kogelmann presented data from a prospectively defined case series evaluating CytoSorb treatment in septic shock patients with multi-organ failure, correlating improved hemodynamic stability and survival when CytoSorb was used within the first 24 hours of septic shock.
  • Dr. Axel Nierhaus and Dr. Dana Tomescu individually described the growing usage of the CytoSorb therapy at their respective hospitals in a variety of different applications.
  • A panel of active CytoSorb users led by Dr. Axel Nierhaus agreed upon the first consensus statement on CytoSorb use, where they concluded:
    • CytoSorb is safe and easy to implement and can be used as an adjunctive therapy to standard medical treatment in patients with septic shock
    • CytoSorb therapy should be administered early after the onset of septic shock (within 6-24 hours) if possible
    • Patients with refractory septic shock may benefit from treatment with CytoSorb if they receive sufficient guideline based resuscitation and achieve good control over the infection
    • More frequent changes of the CytoSorb adsorber should be considered according to the clinical picture and response of the patient
    • All users should take part in the International CytoSorb Registry, which will facilitate better clinical studies in these complex and critically-ill patients

There are more than two dozen new publications involving CytoSorb therapy, ranging from case reports, case series, and small randomized controlled studies that have been submitted or are being prepared for submission to peer-reviewed scientific journals.  These studies report on the use of CytoSorb therapy in a wide range of applications including sepsis, cardiac surgery, post-operative inflammation, liver failure, trauma, and many others.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 42 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial – a multi-center, randomized controlled study that has demonstrated the safety of intra-operative CytoSorb® use in a heart-lung machine during complex cardiac surgery.  In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval.  CytoSorb® has been used safely in more than 17,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant and contract funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb, and others.  For more information, please visit the Company’s websites: and or follow us on Facebook and Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and Twitter

Cytosorbents Contact:
Amy Vogel
Investor Relations
(732) 329-8885 ext. *825
[email protected]

Public Relations Contact:
Amy Phillips
Pascale Communications
[email protected]

Logo –


SOURCE CytoSorbents Corporation